Literature DB >> 12750159

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.

Pascale De Paepe1, Mathijs Baens, Han van Krieken, Bruno Verhasselt, Michel Stul, Annet Simons, Bruce Poppe, Geneviève Laureys, Paul Brons, Peter Vandenberghe, Frank Speleman, Marleen Praet, Chris De Wolf-Peeters, Peter Marynen, Iwona Wlodarska.   

Abstract

We present 3 cases of large B-cell lymphoma (LBCL) with a granular cytoplasmic staining for anaplastic lymphoma kinase (ALK). All of the cases showed striking similarities in morphology and immunohistochemical profile characterized by a massive monomorphic proliferation of CD20-/CD138+ plasmablast-like cells. In one of the cases, initially diagnosed as a null-type anaplastic large cell lymphoma (ALCL), the B-cell phenotype became evident only at recurrence. Fluorescent in situ hybridization (FISH) and molecular studies led to the detection of a CLTC-ALK rearrangement in all 3 cases, without any evidence of full-length ALK receptor expression. The associated t(2;17)(p23;q23) was demonstrated in the karyotype of 2 cases. Although a similar CLTC-ALK aberration was previously identified in ALK-positive T-/null cell ALCL and inflammatory myofibroblastic tumor, its association with ALK-positive LBCL seems to be specific and intriguing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750159     DOI: 10.1182/blood-2003-04-1050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Yasunori Ota; Yasunobu Sekiguchi; Satoko Hatano; Reimi Asaka; Masaaki Noguchi; Hiroyuki Mano
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

2.  Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas.

Authors:  Clare Bedwell; David Rowe; Deborah Moulton; Gail Jones; Nick Bown; Chris M Bacon
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 3.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

4.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

5.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

6.  Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions.

Authors:  Maria K E Blixt; Stephen J Royle
Journal:  Traffic       Date:  2011-03-24       Impact factor: 6.215

Review 7.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 8.  Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting in nasal cavity: a case report and review of literature.

Authors:  Ji Chen; Xiaoli Feng; Mei Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 9.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.